01
Matched comparison methodology
Compare sites in relevant oncology contexts rather than relying on raw averages across unrelated trial designs.
Platform / FIH Scout
FIH Scout maps the execution layer behind oncology trials.
FIH Scout is a site-level intelligence layer for oncology first-in-human trials. It helps sponsors review activation behavior, matched trial context, PI and site behavior, mechanism fit, competitor movement, and global execution risk before operational choices become expensive.
Meet FIH Scout
A site-level intelligence layer for oncology first-in-human trials.
FIH Scout analyzes activation behavior, PI performance, trial history, mechanism fit, sponsor patterns, country risk, and recruitment signals to support smarter FIH planning.
02
PI and site behavior layer
Evaluate investigators based on operational behavior, trial load, and recruitment signal, not only publication prestige.
03
Global site network view
Review US, Europe, APAC, Australia, and China-linked execution patterns to identify concentration and regional strategy risk.
FIH Scout evidence base
Built on a dual-registry view of oncology FIH activity.
The capability layer combines the global clinicaltrials.gov registry with China's ChiCTR registry, then organizes oncology FIH activity by PI, site, sponsor, mechanism, geography, and trial history.
Platform database snapshot queried on 2026-05-30. Public website figures are summarized from the provided capability report and should be reviewed during sponsor diligence.
Global registry and ChiCTR snapshot
Oncology first-in-human subset
Publication and trial-history signal
Sponsor footprint and activity context
Dual-registry coverage
NCT global registry layer for oncology trial activity.
China domestic registry layer, including records not present on clinicaltrials.gov.
FIH-PRS, SRS, and RSS signals
PI, site, and rising-star signals combine publications, trial history, career stage, trial-volume growth, and mechanism-breadth growth. These are descriptive signals, not quality verdicts.
Mechanism-specific re-ranking
A query such as NSCLC + ADC can re-rank PIs and sites toward matched track records rather than presenting one generic leaderboard for all oncology assets.
US/EU historical validation context
In completed US/EU FIH backtests, 48% of actually used sites appeared in the platform Top 10 and 76% in the Top 20. China and India are currently landscape-visibility use cases.
Scope boundariesBacktested Roadmap Out of scope
US/EU site selection; China and India visibility across both registries
China site-level scoring and enrollment-speed signals
NMPA / regulatory-pathway intelligence
China FIH landscape layer
China FIH activity is not fully visible through one registry.
FIH Scout separates clinicaltrials.gov China-only FIH records from ChiCTR domestic-registry records instead of forcing them into a single unsupported number. This matters for China-to-global teams because local activity, mechanism density, and APAC footprint shape the global development conversation.
China and APAC figures are landscape-visibility signals. Multi-site or multi-country trials may be counted once per city or country depending on the view.
Site data confirms all listed locations are in China.
Trial-level domestic registry records not present on clinicaltrials.gov.
Two separately evidenced subsets, shown separately in sponsor work.
Projection based on January-May 2026 starts; actual full-year count may differ.
China FIH mechanism density
APAC FIH footprint
Outputs
Anonymized output modules built for sponsor decisions.
The platform page uses mock examples only. It does not expose confidential site names, private patient data, or unsupported performance claims.
01
Site ranking view
Illustrative site list showing activation signal, PI load, matched trial count, mechanism fit, region, and the reason each site is prioritized or flagged.
02
PI load and prestige risk
Separates investigator reputation from execution capacity so sponsors can identify overloaded prestige centers and emerging operational performers.
03
Competitor density map
Mechanism-specific view of peer trial footprint, country overlap, endpoint choices, and enrollment competition before the site list locks.
04
Global development readiness
Country mix and regional concentration review for US, Europe, APAC, Australia, and China-to-global development paths.
Methodology
Built as an intelligence layer, not a claim of private data access.
FIH Scout combines public trial records, sponsor and site history, mechanism-specific context, licensed or approved data sources where available, and human expert review. It is designed to support better diligence and planning decisions.
- Uses anonymized examples on the public website.
- Does not claim access to private patient data.
- Does not guarantee regulatory approval, enrollment speed, or clinical outcomes.
- Formal sponsor work should proceed with appropriate CDA/NDA boundaries.